Bruce Peterson, MD

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Bruce Peterson

Contact Info

Mailing Address:
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Tracy Daye-Groves

Administrative Phone
612-624-5944

Administrative Email
tmgroves@umn.edu

Administrative Fax Number
612-626-1441

Professor of Medicine, Division of Hematology, Oncology and Transplantation


Medical Oncologist


Medical School, University of Minnesota, Minneapolis, MN

Residency, University of Minnesota, Minneapolis, MN

Fellowship, University of Minnesota, Minneapolis, MN

Summary

Dr. Peterson is a Professor of Medicine in the Division of Hematology, Oncology and Transplantation. He is a graduate of the University of Minnesota Medical School and completed his residency and fellowship at the University.

Awards & Recognition

  • Best Doctors in America® (2011-2012, 2013)
  • MplsSt.Paul Magazine Top Doctors (2012)
  • U.S. News and World Report Top Doctor (2012)
  • St. George's Medal, American Cancer Society (1997)
  • Clinical Excellence Award, University of Minnesota Department of Medicine (2004)
  • Minnesota Monthly "Best Doctors" (2014)

Professional Associations

  • Board of Directors, Minnesota Council, Midwest Division of the American Cancer Society (1991-2001)
  • Chair, Board of Directors, Midwest Division of the American Cancer Society (2010-2011)
  • President, Minnesota Division of the American Cancer Society (1991-1992)

Research

Research Summary/Interests

Dr. Peterson’s clinical and research interests focus on the treatment of hematologic malignancies. He also is the principal investigator for the University of Minnesota Masonic Cancer Center’s NCI-sponsored adult cooperative group program in the Alliance for Clinical Trials in Oncology.

Publications

  • Mulrooney, DA, Ness, KK, Solovey, A, Hebbel, RP, Neaton, JD, Peterson, BA, Lee, CKK, Kelly, AS, Neglia, JS. Pilot study of vascular health in survivors of Hodgkin lymphoma. Pediatr Blood Cancer 59:285-289, 2012.
  • Muskardin T, Peterson BA, Molitor JA. Castleman Disease and Associated Autoimmune Disease. Curr Opin Rheumatol 24:76-83, 2012.
  • Blaes AH, Peterson BA. Hodgkin lymphoma, The Chemotherapy Source Book, Fifth Edition, MC. Perry, editor, Wolters Kluwer Health Lippincott, Williams & Wilkins, Philadelphia, PA 2012.
  • Blaes AH, Ma L, Zhang Y, Peterson BA. Quality of life between indolent and aggressive non-Hodgkin lymphoma survivors appears similar. Leuk Lymphoma 52:2105-2110, 2011.
  • Furman RR, Grossbard, ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma 52(4):587-596, 2011.
  • Wudhikarn K, Holman CJ, Linan M, Blaes AH, Dunitz JM, Hertz ME, Peterson BA. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20 year experience at the University of Minnesota. Clin Transplant 25(2):705-713, 2011.
  • Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Brit J Haematol 151(2):143-151, 2010.
  • Blaes AH, Gaillard P, Peterson BA, Yee D, Virmig B. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 2010 (epub 2010 Jan 8) 122(2):585-590, 2010..
  • Smith SM, Johnson J, Cheson BD, Canellos G, Petroni G, Oken M, Duggan D, Hurd D, Gockerman JP, Parker B, Prchl J, Peterson BA. Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naïve follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-1617, 2009.
  • Bartlett NL, Johnson JL, Wagner-Johnston W, Ratain MJ, Peterson BA. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol 63:793-798, 2009.

Clinical

Clinics

Masonic Cancer Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Clinical Interests

Hematologic malignancies